Replimune price target raised to $21 from $18 at Leerink
Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...
Leerink Partnrs Has Negative Outlook of VKTX FY2025 Earnings
Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Tourmaline Bio FY2024 EPS Forecast Raised by Leerink Partnrs
Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
Fintel on MSN4d
Leerink Partners Upgrades Doximity (DOCS)
Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Biohaven Ltd. (BHVN) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Biohaven Ltd. (BHVN – ...
Investment Banker Cleared to Seek Multi-Million Bonuses Against Former Boston Employer
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
CVS Health's turnaround efforts in focus amid record-high medical costs
CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...
TMCnet8h
T-knife Therapeutics to Participate in Two Investor Conferences in March
SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...
Ex-Goldman Banker Advances Some Pay Claims Against Leerink Firm
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...